Adenoviral (Ad) vectors have emerged as a promising gene delivery platform for a variety of
therapeutic and vaccine purposes during last two decades. However, the presence of …

Adenovirus is a highly evolutionary successful pathogen, as it is widely prevalent across the
animal kingdom, infecting hosts ranging from lizards and frogs to dolphins, birds, and …

Aims We recently reported five cases of vaccine-induced immune thrombotic
thrombocytopenia (VITT) 7–10 days after receiving the first dose of the ChAdOx1 nCoV-19 …

Adenovirus (Ad) vectors are promising candidates for both gene transfer and vaccine
applications. In this study, we investigated the role of TLR2 in innate and adaptive immune …

Kupffer cells (KCs) rapidly remove intravenously injected adenovirus (Ad) vectors from the
circulation. A better understanding of the mechanisms involved could suggest strategies to …

Adenovirus (Ad) vaccine vectors have proven highly immunogenic in multiple experimental
models, but the innate immune responses induced by these vectors remain poorly …

The effects of corticosteroid use on the reactogenicity and immunogenicity of ChAdOx1
nCoV-19 (ChAd) vaccine were evaluated. Healthcare workers (HCWs) who took low-dose …

Adenovirus was first identified in the 1950s and since then this pathogenic group of viruses
has been explored and transformed into a genetic transfer vehicle. Modification or deletion …

Adenovirus (Ad)-based vectors offer several benefits showing their potential for use in a
variety of vaccine applications. Recombinant Ad-based vaccines possess potent …

Understanding innate immunity is key to improving the safety of adenovirus (Ad) vectors for
systemic gene therapy. Ad has been shown to activate complement in vitro, but activation of …